{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:54:42Z","timestamp":1790042082274,"version":"4.0.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.blre.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T18:53:26Z","timestamp":1557600806000},"page":"100578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Cellular therapy for acute myeloid Leukemia \u2013 Current status and future prospects"],"prefix":"10.1016","volume":"37","author":[{"given":"Panupong","family":"Hansrivijit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.05.002_bb0005","series-title":"Research Data (1973\u20132015), National Cancer Institute, Dccps, Surveillance Research Program, Released April 2018, Based on the November 2017 Submission","author":"Surveillance, Epidemiology, and End Results (SEER) Program","year":"2019"},{"issue":"15","key":"10.1016\/j.blre.2019.05.002_bb0010","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2019.05.002_bb0015","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.31370","article-title":"Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.002_bb0025","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2019.05.002_bb0030","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.blre.2019.05.002_bb0040","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.05.002_bb0045","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2013.03.001","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose","volume":"19","author":"Bar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2019.05.002_bb0055","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"Takami","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.blre.2019.05.002_bb0060","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2015-12-688739","article-title":"Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival","volume":"127","author":"Malard","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2019.05.002_bb0065","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1182\/blood-2010-03-273193","article-title":"Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease","volume":"116","author":"Bastien","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbmt.2004.11.015","article-title":"Gammadelta T cells: a new frontier for immunotherapy?","volume":"11","author":"Lamb","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0080","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrclinonc.2016.65","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2019.05.002_bb0085","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-5699(00)01596-6","article-title":"Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis","volume":"21","author":"Moretta","year":"2000","journal-title":"Immunol Today"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MOH.0000000000000384","article-title":"The importance of natural killer cell killer immunoglobulin-like receptor-mismatch in transplant outcomes","volume":"24","author":"Stringaris","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1016\/j.blre.2019.05.002_bb0105","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2019.05.002_bb0110","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","article-title":"Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia","volume":"99","author":"Costello","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0115","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123416","article-title":"Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid Leukemia: a phase I trial","volume":"10","author":"Kottaridis","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.blre.2019.05.002_bb0130","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.05.002_bb0135","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/bmt.2017.122","volume":"52","author":"Nguyen","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.beha.2006.06.004","article-title":"Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation","volume":"19","author":"Passweg","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"357","key":"10.1016\/j.blre.2019.05.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0150","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0155","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of Haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2006-12-022038","article-title":"The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia","volume":"110","author":"Chakraverty","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0165","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0170","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.4049\/jimmunol.167.6.3129","article-title":"Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15","volume":"167","author":"Dunne","year":"2001","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.blre.2019.05.002_bb0175","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2019.05.002_bb0180","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.002_bb0185","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"Jaiswal","year":"2017","journal-title":"Cytotherapy"},{"issue":"25","key":"10.1016\/j.blre.2019.05.002_bb0195","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.05.002_bb0200","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood-2017-05-785659","article-title":"Interim results of a phase 2 clinical trial using Mb-IL21 <em>ex vivo<\/em> expanded NK cells to enhance graft versus Leukemia effect for patients with myeloid malignancies after Haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2019.05.002_bb0205","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","article-title":"A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid Leukemia","volume":"24","author":"Fehniger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2019.05.002_bb0210","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2017-08-752170","article-title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation","volume":"131","author":"Cooley","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.blre.2019.05.002_bb0220","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF02983217","article-title":"Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells","volume":"77","author":"Hongeng","year":"2003","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2019.05.002_bb0225","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2009.019885","article-title":"Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation","volume":"95","author":"Kuci","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0230","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3892\/or.2013.2315","article-title":"Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells","volume":"29","author":"Wang","year":"2013","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","article-title":"The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells","volume":"14","author":"Rettinger","year":"2012","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.blre.2019.05.002_bb0240","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V86.9.3493.bloodjournal8693493","article-title":"Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells","volume":"86","author":"Mehta","year":"1995","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2019.05.002_bb0245","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Schmidt-Wolf","year":"1993","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/cimm.1996.0094","article-title":"Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells","volume":"169","author":"Schmidt-Wolf","year":"1996","journal-title":"Cell Immunol"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2009.01.010","article-title":"Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes","volume":"37","author":"Franceschetti","year":"2009","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.blre.2019.05.002_bb0260","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.4049\/jimmunol.175.12.7819","article-title":"Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells","volume":"175","author":"Karimi","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.blre.2019.05.002_bb0265","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2019.05.002_bb0270","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/14653249.2012.694419","article-title":"A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission","volume":"14","author":"Linn","year":"2012","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.blre.2019.05.002_bb0275","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-014-1618-7","article-title":"Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia","volume":"100","author":"Wang","year":"2014","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0280","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.bbmt.2015.11.324","article-title":"Preemptive treatment of minimal residual disease (MRD) with IL-15-activated cytokine-induced killer cells for the prevention of relapse in Leukemia patients after allogeneic stem cell transplantation \u2013 results of a pilot study","volume":"22","author":"Bader","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.05.002_bb0285","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.V128.22.1160.1160","article-title":"Final analysis of a multicenter pilot phase 2 study of cytokine induced killer (CIK) cells for patients with relapse after allogeneic transplantation","volume":"128","author":"Lussana","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-017-0519-7","article-title":"Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia","volume":"10","author":"Fan","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"37","key":"10.1016\/j.blre.2019.05.002_bb0295","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1002\/anie.201405353","article-title":"Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia","volume":"53","author":"Lu","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0300","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/leu.2016.328","article-title":"PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia","volume":"31","author":"Goltz","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.blre.2019.05.002_bb0305","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2019.05.002_bb0310","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2019.05.002_bb0315","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.05.002_bb0320","first-page":"1376","article-title":"Autologous T cells modified to co-express CD33-specific chimeric antigen receptor and a kill switch for treatment of CD33<sup>+<\/sup> acute myeloid Leukemia","volume":"130","author":"Song","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.05.002_bb0325","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid Leukemia with T cells expressing chimeric antigen receptors directed to C-type Lectin-like molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and Transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.blre.2019.05.002_bb0335","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2019.05.002_bb0340","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0345","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2019.05.002_bb0350","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood-2018-99-114572","article-title":"Specific targeting of acute myeloid Leukemia by the use of non-virally engineered CIK (cytokine-induced killer) cells expressing the anti-CD33 chimeric antigen receptor (CAR)","volume":"132","author":"Rotiroti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.05.002_bb0355","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2018-99-111326","article-title":"Remissions in relapse\/refractory acute myeloid Leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy","volume":"132","author":"Sallman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.05.002_bb0360","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2018-99-118230","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate hematopoietic stem and CD117-positive AML cells","volume":"132","author":"Myburgh","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0365","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.4049\/jimmunol.167.4.2068","article-title":"A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells","volume":"167","author":"Screpanti","year":"2001","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0370","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1371\/journal.pone.0000326","article-title":"Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies","volume":"2","author":"Bhat","year":"2007","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0375","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.blre.2019.05.002_bb0380","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0385","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.blre.2019.05.002_bb0390","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.blre.2019.05.002_bb0395","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0400","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0405","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"Muller","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2019.05.002_bb0410","first-page":"4453","article-title":"Cord blood NK cells engineered to express a humanized CD123-targeted chimeric antigen receptor (CAR) and IL-15 as off-the-shelf therapy for acute myeloid Leukemia","volume":"130","author":"Kerbauy","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2019.05.002_bb0415","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0420","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.blre.2019.05.002_bb0425","first-page":"4516","article-title":"Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk Leukemia and lymphoma patients after HCT","volume":"130","author":"Williams","year":"2017","journal-title":"Blood"},{"issue":"5796","key":"10.1016\/j.blre.2019.05.002_bb0430","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0435","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-cell receptor-engineered T cells for cancer treatment: current status and future directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0440","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0445","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0450","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"174","key":"10.1016\/j.blre.2019.05.002_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2019.05.002_bb0460","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","article-title":"TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1","volume":"129","author":"Jahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0465","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.15078","article-title":"Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword","volume":"181","author":"Hobo","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2019.05.002_bb0470","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of gammadelta T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.002_bb0475","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.05.002_bb0480","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \"off-the-shelf\" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"issue":"15","key":"10.1016\/j.blre.2019.05.002_bb0485","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful transfer of umbilical cord blood CD34(+) hematopoietic stem and progenitor-derived NK cells in older acute myeloid Leukemia patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.blre.2019.05.002_bb0490","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","article-title":"Larger size of donor Alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid Leukemia patients","volume":"22","author":"Curti","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0495","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2019.05.002_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027351","article-title":"IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I\/II study","volume":"6","author":"Brehm","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.blre.2019.05.002_bb0505","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.3324\/haematol.2015.138016","article-title":"Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy","volume":"101","author":"Rettinger","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2019.05.002_bb0510","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.bbmt.2010.05.015","article-title":"Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation","volume":"16","author":"Introna","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2019.05.002_bb0515","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2019.05.002_bb0520","first-page":"159","article-title":"Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia","volume":"12","author":"Benyunes","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2019.05.002_bb0525","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.blre.2019.05.002_bb0530","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exphem.2017.06.007","article-title":"Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia","volume":"54","author":"Laing","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2019.05.002_bb0535","first-page":"1","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","author":"Baron","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.blre.2019.05.002_bb0540","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1038\/bcj.2017.52","article-title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","volume":"7","author":"Xie","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.blre.2019.05.002_bb0545","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1038\/bcj.2011.12","article-title":"FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes","volume":"1","author":"Brackertz","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2019.05.002_bb0550","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.V128.22.1072.1072","article-title":"Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid Leukemia","volume":"128","author":"Chien","year":"2016","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:38Z","timestamp":1759436618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18301231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":110,"alternative-id":["S0268960X18301231"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.05.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular therapy for acute myeloid Leukemia \u2013 Current status and future prospects","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100578"}}